Payment overview · 2025
General Payments
$1,700.10
97 reported records · 23 companies
Healthcare provider profile · identity verified
John Manchin, DO
Allopathic & Osteopathic Physicians|Family Medicine · FARMINGTON, WV · NPI 1134231640
Verified facts
What the public records show
CMS Open Payments records show John Manchin, DO received $1,700.10 in general payments during 2025 across 97 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $282.76 | 16.6% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.34 | 12.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $207.84 | 12.2% | 16 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $136.78 | 8.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.76 | 8.0% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $124.69 | 7.3% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.53 | 6.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.33 | 4.1% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $60.84 | 3.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $60.49 | 3.6% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $36.03 | 2.1% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $32.92 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.04 | 1.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.97 | 1.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $23.23 | 1.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.01 | 1.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.33 | 1.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.36 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.02 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.96 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $17.31 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.88 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.68 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,700.10 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $161.73 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $157.84 | 8 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $155.62 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.57 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.79 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $124.69 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.75 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.86 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $104.53 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.55 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.17 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.95 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $60.84 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $60.49 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $56.61 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $45.90 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 271 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
271 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
198 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1111 | 186 |
| Omeprazole | Omeprazole | 902 | 246 |
| Atorvastatin Calcium | Atorvastatin Calcium | 894 | 249 |
| Lisinopril | Lisinopril | 854 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 795 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 674 | 176 |
| Gabapentin | Gabapentin | 661 | 123 |
| Losartan Potassium | Losartan Potassium | 645 | 178 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 596 | 167 |
| Pantoprazole Sodium | Pantoprazole Sodium | 575 | 160 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 511 | 146 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 462 | 110 |
| Metformin Hcl | Metformin Hcl | 442 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 365 | 104 |
| Sertraline Hcl | Sertraline Hcl | 355 | 95 |
| Fluticasone Propionate | Fluticasone Propionate | 313 | 139 |
| Furosemide | Furosemide | 300 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 71 |
| Ibuprofen | Ibuprofen | 292 | 116 |
| Potassium Chloride | Potassium Chloride | 288 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 67 |
| Trazodone Hcl | Trazodone Hcl | 273 | 75 |
| Ozempic | Semaglutide | 271 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 256 | 80 |
| Azithromycin | Azithromycin | 254 | 193 |
| Montelukast Sodium | Montelukast Sodium | 248 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 77 |
| Simvastatin | Simvastatin | 245 | 80 |
| Tramadol Hcl | Tramadol Hcl | 236 | 63 |
| Quetiapine Fumarate | Quetiapine Fumarate | 218 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 60 |
| Eliquis | Apixaban | 198 | 50 |
| Methylprednisolone | Methylprednisolone | 198 | 156 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 50 |
| Famotidine | Famotidine | 181 | 39 |
| Buspirone Hcl | Buspirone Hcl | 180 | 47 |
| Meloxicam | Meloxicam | 180 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 49 |
| Warfarin Sodium | Warfarin Sodium | 172 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 169 | 127 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 45 |
| Atenolol | Atenolol | 153 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 39 |
| Amoxicillin | Amoxicillin | 143 | 114 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 46 |
| Jardiance | Empagliflozin | 133 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 129 | 96 |
| Lorazepam | Lorazepam | 123 | 39 |
| Naproxen | Naproxen | 123 | 49 |
| Allopurinol | Allopurinol | 121 | 34 |
| Mupirocin | Mupirocin | 121 | 82 |
| Carvedilol | Carvedilol | 120 | 34 |
| Cephalexin | Cephalexin | 115 | 99 |
| Fluconazole | Fluconazole | 114 | 66 |
| Metformin Hcl Er | Metformin Hcl | 112 | 38 |
| Ezetimibe | Ezetimibe | 111 | 39 |
| Clonidine Hcl | Clonidine Hcl | 110 | 47 |
| Ondansetron Odt | Ondansetron | 110 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 105 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 25 |
| Pregabalin | Pregabalin | 102 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 34 |
| Methocarbamol | Methocarbamol | 95 | 46 |
| Donepezil Hcl | Donepezil Hcl | 94 | 15 |
| Mometasone Furoate | Mometasone Furoate | 94 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 78 |
| Lovastatin | Lovastatin | 88 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 85 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 33 |
| Prednisone | Prednisone | 80 | 55 |
| Nystatin | Nystatin | 79 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 24 |
| Meclizine Hcl | Meclizine Hcl | 72 | 29 |
| Spironolactone | Spironolactone | 72 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 20 |
| Clonazepam | Clonazepam | 69 | 16 |
| Glimepiride | Glimepiride | 69 | 20 |
| Vascepa | Icosapent Ethyl | 69 | 24 |
| Trulicity | Dulaglutide | 68 | 18 |
| Januvia | Sitagliptin Phosphate | 62 | 24 |
| Lidocaine | Lidocaine | 62 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Mounjaro | Tirzepatide | 61 | 19 |
| Celecoxib | Celecoxib | 59 | 22 |
| Linzess | Linaclotide | 59 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 16 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | 18 |
| Glipizide | Glipizide | 57 | 15 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 14 |
| Xarelto | Rivaroxaban | 55 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 49 | 16 |
| Lamotrigine | Lamotrigine | 49 | 11 |
| Novolog Flexpen | Insulin Aspart | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 20 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 12 |
| Propranolol Hcl | Propranolol Hcl | 43 | 13 |
| Myrbetriq | Mirabegron | 40 | 11 |
| Lansoprazole | Lansoprazole | 39 | 14 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 13 |
| Topiramate | Topiramate | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Cefdinir | Cefdinir | 35 | 31 |
| Levofloxacin | Levofloxacin | 35 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 14 |
| Temazepam | Temazepam | 33 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | 11 |
| Estradiol | Estradiol | 28 | 11 |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Permethrin | Permethrin | 28 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Erythromycin | Erythromycin Base | 26 | 20 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 21 | 12 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Colchicine | Colchicine | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,700.10 · 97 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, BRILINTA, CREON, CRYSVITA, Cologuard Collection Kit, EVENITY, FARXIGA, FASENRA, FLOWTRIEVER, Flector, JARDIANCE, Kerendia, LINZESS, LOREEV XR, Licart, NEFFY, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, VOQUEZNA, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZORYVE, t:slim X2 Insulin Pump with Control-IQ | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error